Clinical outcomes after ablation of persistent atrial fibrillation remain suboptimal. Identification of AF drivers using a novel integrated mapping technique may be crucial to ameliorate the clinical outcome.
I
n the past 3 decades, radiofrequency catheter ablation has developed from an experimental procedure to a valid and well-established treatment option for many patients affected by atrial fibrillation (AF). 1 However, the high efficacy of this procedure in paroxysmal AF is counterbalanced by suboptimal clinical results when dealing with the persistent form; for this reason, the treatment strategy in this subset of patients is still under debate. [2] [3] [4] In fact, our incomplete understanding of the AF mechanisms has led to a wide range of approaches targeting atrial substrate in addition to pulmonary vein (PV) isolation. 5 Recent clinical studies have demonstrated that AF in humans could be sustained by regular and organized sources and that radiofrequency catheter ablation targeting the regions showing highest dominant frequency or eliminating electric rotors resulted in high rates of acute AF termination and improved long-term clinical outcome. [6] [7] [8] [9] [10] These approaches, although promising, imply complex mathematical analysis to identify potential mechanisms 7, 8 and do not necessarily localize the regions of interest during real time on a 3-dimensional (3D) map. 8 Recent observations have demonstrated that real-time localization of potential AF sources and their propagation through the neighboring regions, associated with the visualization of anatomic and functional substrates, is feasible and can be assessed using a novel integrated mapping technique. 11 The identification of the electrophysiological substrate in each individual patient may potentially lead to a mechanisms-targeted ablation strategy because the elimination of these sources might improve the clinical outcome. To confirm this hypothesis, the primary objective of this prospective randomized study was to assess the efficacy of an electrophysiological guided ablation strategy in a cohort of patients with persistent AF (PersAF).
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure because at the time of study start, this permission was not implemented in the patient-informed consent. The trial was conducted in accordance with the Declaration of Helsinki.
Study Design
This trial was a prospective, single-center, randomized (before ablation) study evaluating the effectiveness of adjunctive repetitive-regular activities (RRas) ablation on top of modified circumferential pulmonary vein ablation (mCPVA) for the treatment of PersAF. Consenting eligible subjects were randomly assigned (1:1) to undergo a patienttailored mapping-guided ablation plus mCPVA (mapping
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• To date, several techniques have been used to identify potential atrial fibrillation sources.
WHAT THE STUDY ADDS?
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group) or mCPVA alone (control group; Figure 1 ). The study protocol was approved by the institutional ethics committee, and all patients provided written informed consent.
Study Population
Consecutive patients undergoing radiofrequency catheter ablation for drug-refractory PersAF were included (Table 1) . Exclusion criteria were paroxysmal AF, presence of intracardiac thrombi, uncontrolled heart failure, severe valvular disease, and left atrium (LA) dimension >35 cm 2 . Exclusion criteria included reversible causes of atrial arrhythmia (such as hyperthyroidism, pneumonia, pulmonary embolism, sarcoidosis, and excessive alcohol consumption) and pregnancy. Patients with 1 previous AF ablation were accepted in the study.
AF Mapping Procedure
Our standard approach has been previously described in detail. 12 The mapping and ablation procedures were guided by a commercial EnSite Velocity (Abbott) system and in parallel an EnSite Velocity system with a dedicated research software (Abbott). An Inquiry AFocusII catheter (Double Loop, 20 pole, Abbott) was advanced transeptally as it was used to perform the electrophysiological LA map. After randomization, a high-density map was collected in each patient, before ablation although the patient was in AF. In the control group, the electrophysiological map was blinded to the physician operator. During each mapping procedure, bipolar intracardiac electrograms were recorded continuously for 5 to 10 s at each catheter location using the mapping catheter. At each mapped region, the multipolar catheter was not moved during the recording time. The software analyzed the recorded electrograms in this predefined 5 to 10 s window, calculating peak-to-peak voltage and cycle length (CL) for each spatial point. The peak-to-peak voltage map used a dedicated algorithm (0.05 mV sensitivity, 80 ms refractory period) to detect local activations during mapping time. During AF, the peak-to-peak voltage was measured for each discrete electrogram activation, from the point of highest to lowest amplitude, and averaged for the entire acquisition window. Electrogram signal stability and quality were assessed by the operator during the time of acquisition to visually pre-screen when enough signal has been collected.
AF Substrate Map
This technique using the novel mapping software is described in Methods in the Data Supplement in detail. In brief, a Regular Cycle Length Map was used to identify and measure the average CLs of the repetitive-regular electrograms during AF. The regions showing repetitive and regular activations with a mean CL ≤220 ms and a CL SD between 0 to 30 ms were considered as ablation target. These sources had the following characteristics: distinct peak-peak activations, small variation in activation CL (SD, 0-30 ms), consistent electrogram morphology, flat isoelectric interval between consecutive activations and consistent activation sequences on the multielectrode mapping catheter over time ( Figure I in the Data Supplement). During acquisition, the software analyzed the CL and variability of electrograms, whereas morphology was assessed by the operator. In addition, conduction velocity (CV) vectors were calculated to identify the wavefront propagation direction and speed of the repetitive-regular activations (Methods in the Data Supplement). A temporal consistency index (ranging from 0 to 1) of CV is computed to quantify how consistent the local wavefront propagation is during the entire mapping segment length. A fragmentation map is constructed according to the fractionation index that is measured by an automatic algorithm to show the regions exhibiting fragmented electrograms ( Figure II in the Data Supplement). Characteristics of fragmented electrograms are described in Methods in the Data Supplement. A peak-to-peak voltage was measured during the total length of recording time. All of the abovementioned mapping features are displayed into 1 integrated map to simultaneously visualize all the electrophysiological characteristics during AF. Regions with RRa (eg, potential drivers) were displayed in rainbow color spectrum, whereas regions exhibiting fragmented electrograms were shown in brown spectrum with darker shades representing higher degree of fragmentation (faster average CL among the local electrogram peaks). Regions with voltage <0.05 mV are colored in grey. A region with RRa electrograms was defined from a group of adjacent mapping points having the same mean CLs within a range of 0 to 30 ms CL variability. Regions showing RRa were separated by their local mean CL, detected from the highest peak of consecutive activations. Neighboring regions with RRa were separated as discrete sites according to their average CL. Intermittent activations were considered irregular and filtered out by the automatic software analysis. Irregular activations (>30 ms variability), fractionation (60-120 ms CL), and regions with voltage <0.05 mV were excluded for AF sources identification. The software analyzed temporal electrograms for repetitive-regular activations (120-220 ms activation and 0-30 ms variability), filtering out the regions with electrograms that degenerated in CL (high temporal variability). In addition, it does not provide a color code for those regions showing irregular activations, not fast enough to be fragmented and not consistent and regular enough to be considered as repetitive-regular sites. CV 3D arrows are displayed on top of the color maps, with the tip of the arrow pointing in the direction of the local wavefront propagation. A representative example of an integrated substrate map is shown in Figure 2 . AF electrophysiological maps were analyzed during the procedure to guide ablation for the mapping group, and postprocedurally in the control group, which was substrate blinded to the operator.
Radiofrequency Catheter Ablation
After having acquired the AF substrate map, RF energy was delivered with a 3.5-mm tip irrigated catheter (FlexAbility; Abbott) in both groups. In the mapping group, radiofrequency catheter ablation always commenced treating regions showing RRa, targeting the fastest sources first and subsequently the slower. The end point was elimination of all the previously identified RRa. The ablation strategy differed according to RRa distribution: encircling of the identified region (eg, PV related), point-by-point ablation covering the entire region, or by linear lesion (eg, roof or posterior Figure If an RRa region fell outside the usual mCPVA, point-by-point ablation encompassing the area was performed. Each pointby-point RF application lasted 30 to 60 s until local bipolar electrogram abolition by potential reduction ≤0.1 mV before moving to another site. In the mapping-guided group, the first ablation site was represented by the fastest area, whereas the successive regions with slower (in descending order) CL were subsequently targeted. Ablation at RRa regions was followed by mCPVA in the mapping group, whereas it was performed as sole therapy in the control group. The standard mCPVA lesions set included circumferential pulmonary vein ablation, mitral isthmus line, roof, and posterior line, as previously described. 12 In both groups, at the end of ablation and during sinus rhythm, both linear lesions (posterior box and mitral line) either PV isolation were documented by pacing maneuvers using the multipolar mapping catheter. Electric PV isolation was considered successful when PV potentials disappeared or were disconnected (entry block), and when pacing at 10 mA and a pulse width of 1 ms from all mapping catheter bipolar electrodes allowed local capture without LA capture (exit block).
Postablation Management and Follow-Up
After discharge, patients were scheduled at 3, 6, and 12 months for follow-up visits with baseline ECG and 24-hour Holter recordings. Arrhythmia recurrence was detected using implantable cardiac monitors (ICM) or transtelephonic and 24-hour ECG Holter monitoring. Recurrent left atrial tachycardia (AT) was characterized from 12-lead ECG or 24-hour ECG Holter with availability of 12-lead ECG and confirmed by redo procedures when performed. Previously ineffective antiarrhythmic drugs were continued for 3 months, and after that time, their discontinuation was recommended. All repeat ablation procedures were performed using the conventional 3D mapping approach without the use of this software.
End Point of the Study
The purpose of this prospective randomized clinical study was to evaluate the acute and 1-year clinical outcome of a novel targeted approach for catheter ablation therapy. The primary objective was to assess the single procedure freedom from any recurrent atrial tachyarrhythmia (ATa). Recurrence was defined as ATa of >2 minutes duration during the follow-up. Any episode occurring in the blanking period was not considered. Secondary end points were to assess change in atrial fibrillation cycle length (AFCL) per strategy and incidence of intraprocedural AF termination. In addition, the AF mechanisms in terms of RRa anatomic location, propagation, and electrophysiological characterization of the LA substrate during clinical arrhythmia using a novel mapping technique were also assessed.
Sample Size and Statistical Analysis
In subjects with PersAF, it is possible to demonstrate a 1-year clinical difference among the 2 therapies with a significance level of 0.5 and a power of 0.80 using a log-rank test in 38 subjects per group, estimated success of 50% and 80% in the control arm and mapping arm, respectively. The expected difference is based on extensive experience of the operators. Considering 5% dropout rates, thus a total of 80 subjects will be included and assigned to either treatment group according to a randomization schedule stratified by the previous ablation procedures (none and 1 previous ablation procedure). Categorical and continuous variables are expressed as absolute and relative frequencies or as mean±SD or median (interquartile range) as appropriate. Comparisons of continuous variables were done with a Student t test or the MannWhitney U test as appropriate and binomial variables with χ or Fisher test. Long-term outcome was assessed, after a single ablation procedure, by Kaplan-Meier method and compared using the log-rank test. A 2-tailed probability value of ≤0.05 was deemed significant. Statistical analyses were conducted using SPSS (SPSS v22).
RESULTS

Study Population
A total of 81 patients (male 74%; mean age, 61.7±10.6) with PersAF were enrolled in the study (Figure 1 ). After having assessed inclusion/exclusion criteria, subjects were randomized into mapping group (n=41) or control group (n=40), respectively. All patients had failed a mean of 1.6±0.9 antiarrhythmic drugs and all of them had undergone at least 1 external electric cardioversion in the year before ablation. There were 61 of 81 (75%) patients undergoing first-time ablation (31/40 in the control group versus 30/41 in the mapping group; P=0.79). AF duration from diagnosis was 4.5±5.3 years (range, 1.8-10.2 years), and mean duration of AF persistency was 6.1±1.4 months (range, 4-11 months). The study population baseline clinical characteristics are listed in Table 1 .
AF Drivers Identification and Characterization
A mean 2367±936 points per map were collected before ablation: 2280±1117 in the mapping and 2432±1133 in the control group (P=0.54). The baseline mean AFCL was 172.3±38.9 ms: 174.3±35.3 ms in mapping and 170.8±42.2 ms in control group, respectively (P=0.79). The LA was divided into 11 regions for RRa electrogram analysis (Figure 3) . The total number of LA regions exhibiting RRa was 479 in 81 patients: 232 regions in 41 mapping patients, whereas 247 regions in 40 control group patients (P=0.11). Only 1 patient in the mapping group had a highly fragmented substrate with RRa located in the LAA. The total mean number of RRa per patient was 5.9±2.4 (5.7±2.3 in mapping versus 6.2±2.5 in control group; P=0.35; Table 2 ). In the study population, among all documented RRa, 185 of 479 (39%) were identified in the antrum of PVs (92/232, 40% in mapping versus 93/247, 38% in control group), whereas the remaining 294 of 479 (61%) were located in non-PV regions (140/232, 60% in mapping versus 154/247, 62% in control group; PV versus non-PV RRa; P=0.71; Figure 3) Table 2 ). The 170 ms cutoff has been selected, based on the average RRa CL in the overall study cohort ( Table 2 ). The fragmented electrograms were frequently observed at the periphery of the RRas. Regions of fractionation accounted for a total distribution area of 22.6±16.8% of the LA surface, and it was similar in both groups (mapping 21.9±15.5% versus control 23.5±17.3%; P=0.66). Among all electrograms recorded, the mean voltage (excluding areas <0.05 mV) was 0.60±0.23 mV. In addition, regions with voltage <0.05 mV accounted for a total surface area of 9.3±7.4% during AF.
Catheter Ablation Acute Procedural Details
Mapping Group
Mapping-guided ablation resulted in intraprocedural arrhythmia termination in 25 patients (25/41, 61%), whereas the remaining subjects (16/41, 39%) experienced a significant AFCL prolongation (184.7±53.3 ms versus 211.4±53.1 ms; P=0.007). With the addition of mCPVA, none of the patients converted to sinus rhythm, but AFCL further prolonged (from 211.4±53.1 to 258.5±99.2 ms; P=0.02). AF termination during ablation occurred at the regions exhibiting RRa (Movies IIIa, IIIB, IVA, and IVB in the Data Supplement): 9 of 25 (36%) at the fastest sites, and 16 of 25 (64%) at the slower targets. Sites of AF termination included non-PV regions in 17 of 25 (68%; Figure 4 ). In this group, AF directly converted to sinus rhythm in 21 of 25 (84%), whereas it changed in AT/Aflutter in the remaining 4 of 25 (16%) subjects. The mechanisms of these arrhythmias were 1 septal AT ablated from both left and right side, 2 right isthmus-dependent flutter, and 1 right-sided AT terminated at superior vena cava. All AT/Aflutter occurring during the procedure have been mapped and successfully ablated. Moreover, 5 other patients received right isthmus ablation for previously documented typical Aflutter.
Control Group
A total of 12 of 40 (30%) individuals converted to sinus rhythm during ablation, whereas in the remaining 28 of 40 (70%), the AFCL prolonged when compared with baseline (188.6±45.6 versus 213.5±56.2 ms; P<0.001). Eight patients also received right isthmus ablation. The AF termination rate was significantly lower when compared with the mapping-guided strategy (30 versus 61%; P=0.007). Sites of AF termination included non-PV regions in 9 of 12 (75%). Total RF duration (P=0.38), mapping (P=0.46), and fluoroscopy times (P=0.69) were not significantly different between the groups ( Table 2) . Table 3 shows details of procedural outcome for both groups.
Procedural Complications
Two patients (2.5%), 1 per group, respectively (P=1.00), experienced mild pericardial effusion not requiring drainage. Two patients experienced femoral pseudoaneurysm (2/81, 2.5%; 1 per group; P=1.00), one of them requiring surgical treatment. None of patients died or experienced cerebrovascular events in the periprocedural period and during the entire follow-up.
One-Year Clinical Outcome
All 81 patients completed the 1-year follow-up. Figure 5 shows clinical outcome of patients according to the ablation strategy. Among 81 patients, 57 (70.3%) received an ICM (29/40, 72.5% in control versus 28/41, 68.3% in mapping group; P=0.80), whereas the remaining 24 of 81 subjects (29.6%; 32% in mapping versus 27% in control group) received event transtelephonic and 24-hour ECG Holter monitors. Overall, freedom from ATas after a single procedure was achieved in 50 of 81 patients (61.7%). After a single procedure, at 1-year follow-up, patients in mapping group had a higher success rate in terms of freedom from ATa recurrences when compared with control group (30/41, 73.2% versus 20/40, 50%; P=0.03; Figure 5 ).
Among those monitored only with ICM, 71.4% (20/28) of patients in the substrate-targeted group had no recurrences when compared with 41.3% (12/29) in the control arm (P=0.02) at 12-month follow-up. However, of 25 subjects with ICM experiencing ATa recurrences (8 in mapping and 17 in control group), an AT/ AF burden <20% during the follow-up was documented in 5 of 8 (62.5%) of mapping and 8 of 17 (47.1%) of control group, respectively (P=1.00).
Most of the recurrences were documented as AF (59%), 15% as Aflutter and 26% as left AT. Overall, 16 patients (5 substrate versus 11 control group; P=0.71) underwent a redo procedure because of AF (2 mapping versus 5 control group; P=1.00), Aflutter (2 mapping versus 3 control group; P=1.00), and left AT (1 mapping versus 3 control group; P=1.00). Among 11 patients undergoing a repeat LA procedure (11/16, 68.7%), at least 1 PV reconnection occurred in 6 (54.5%), whereas reconduction through the lines (posterior box or mitral isthmus) was documented in 7 (63.6%) and 4 (36.4%) of them, respectively.
DISCUSSION
Main Findings
To the best of our knowledge, this is the first prospective randomized study assessing the role of a novel provides an adjunctive benefit to mCPVA in terms of ATa freedom at 1-year follow-up (73.2% in mapping versus 50% in control group; P=0.03); and (2) mechanisms-guided strategy results in higher incidence of acute arrhythmia termination and a more significant prolongation in AFCL when compared with conventional approach.
AF Drivers Characterization and Acute Ablation Results
Although previous studies have demonstrated that PVs and PV antrum may trigger AF, particularly in patients with paroxysmal AF, 2, 3 there is substantial evidence that non-PV regions (appendage, roof, posterior wall, septum, coronary sinus) may be more involved in persistent and long-standing PersAF. 13 However, the underlying electrophysiological patient-specific mechanisms that sustain AF remain unclear in the majority of PersAF subjects, resulting in suboptimal ablation outcome in this setting. In this uncertainty, several methods, including phase mapping, 14 activation, 15, 16 and body surface mapping, 17 have been used to study AF propagation in humans in the attempt to identify the potential leading mechanisms and to design tailored ablation strategies. 15, [18] [19] [20] In fact, the presence of drivers has been documented in the animal model and demonstrated in the humans during endocardial and epicardial mapping with the use of multielectrode tools or noninvasive torso electrode arrays by using activation, spectral, or phase mapping. 21, 22 More recently, physiological mapping of AF has been used to identify areas of the atrium that may be responsible of maintaining AF. 11 Narayan et al 8 have elegantly demonstrated the presence of stable rotors and focal sources using computational optical mapping in humans and that ablation targeting such regions results in high rates of acute termination and long-term freedom from recurrent AF. The latter approach, although promising, did not imply a realtime visualization of the electrophysiological substrate during AF on a 3D mapping system.
The main characteristic of the technique described herein is the identification of electrograms with high temporal regularity in the time domain (regular CL map). The difference between regular CL map and dominant frequency map is that the former performs the analysis in time domain, whereas the latter in frequency domain. Regular CL map identifies the electrograms with high CL regularity and characterizes the CLs of these regular activations. Electrograms that did not have regular activations did not have a regular CL value assigned to those map points. However, every electrogram, regardless of having regular activations or not, has a dominant frequency, obtained from Fast Fourier Transform. Dominant frequency analysis does not differentiate electrograms with regular intervals and morphology. For AF electrograms with high variability of the activation intervals and complex fractionation, it is unclear if any of the analysis in frequency domain corresponds to the atrial activation rate. Therefore, the technique described in this study represents the first attempt to identify discrete drivers; however, further studies are needed to characterize the electrophysiological properties of this repetitive-regular electrograms (microreentries, rotors, focal sources, etc.).
We report our experience using this novel mapping technique, which allows a real-time localization of potential AF sources and their propagation through the neighboring regions, associated with the visualization of anatomic and functional substrates. 11 According to these observations, this study was designed to assess the clinical value of repetitive-regular electrograms elimination by catheter ablation. As observed in our series, this strategy afforded a very high incidence of acute arrhythmia termination when compared with conventional approach, suggesting that these sources maintained AF in this patient cohort. This might indicate that the repetitive and organized activities could serve as AF drivers, thus proposing their abolition as a desirable end point for the ablation procedure. Furthermore, this contribution aligns well with previous experiences, which have demonstrated the importance of low-voltage areas, that contain potential AF sources and their ablation ameliorates arrhythmia freedom rates. 23, 24 In fact, in our study, repetitive-regular sites showed a mean voltage 0.5 to 0.6 mV, which is in line with Jadidi et al 23 and Yagishita et al. 24 Among the identified repetitive-regular activation sites, 74% were surrounded by fractionation. On the basis of these findings, one might speculated that RRas could cause fragmentation in the neighboring regions. The hypothesis that fractionation might be a dependent phenomenon 24, 25 could be supported by previous observations describing fragmented electrograms when rapidly propagating impulses collide with functional (heterogeneous tissue properties) or anatomic barriers (scar/fibrosis). 25, 26 The abovementioned hypotheses might also explain the conflicting clinical results after CFAE ablation [27] [28] [29] ; however, it is still under debate which are the critical sites maintaining nonparoxysmal AF. In our work, we have hypothesized that RRas could serve as AF drivers. In fact, the latter electrograms have been targeted, thus resulting in acute arrhythmia termination and better clinical outcome in the follow-up, in the majority of the cases. Future studies will further characterize the electrophysiological properties of these regions. Moreover, this mapping software might also serve as a diagnostic tool to identify several AF mechanisms in each individual patient to tailor ablation strategy according to patient-specific arrhythmogenic substrate and operator experience.
Overall, ablation time did not statistically differ among the groups. Mapping-guided ablation was always followed by mCPVA, whose set of lesions generally encompasses the majority of drivers. Therefore, after RRa ablation, few lesions were missing to cover the standard mCPVA, determining a nonsignificant increase in ablation time. Although similar set of lesions has been performed in both groups, the difference in clinical outcome might be explained by the fact that abolition of repetitive-regular electrograms itself determined an adjunctive clinical benefit as a consistent number of potential AF sources fell outside a standard CPVA. Finally, these results may also suggest that lines or other lesions performed without a clear electrophysiological target may not represent the adequate treatment in this subset of patients.
Clinical Implications of AF Driver Ablation
The mechanisms and substrates that maintain AF may vary in every patient. As a result, there is urgent need to identify mechanisms of AF in individual subject, to potentially pursue drivers-targeted AF ablation approach. There is substantial evidence in the literature from animal models, suggesting that rotors/ focal sources are the mechanisms that drive AF, 30 and although their existence in humans has been questioned, rotors are increasingly revealed in human AF by several investigators using various approaches. 14, 21, 22, [25] [26] [27] Furthermore, when drivers are targeted by ablation, their subsequent elimination results in high acute AF termination rate and better long-term clinical outcome. 11, 12, 28, 29 Although the anatomic distribution of drivers may vary according to patients' characteristics and arrhythmia duration, as occurred in our series we observed and confirmed the importance of non-PV regions in AF maintenance. Our results demonstrated that drivers elimination approach may be beneficial to ameliorate the clinical outcome after PersAF ablation when compared with mCPVA alone, at 1-year followup, reaffirming the current evidence that patients with nonparoxysmal AF should receive additional substrate ablation to improve outcome. 1 However, the results of the STAR-AF-II trial (Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial Part II) have recently questioned the abovementioned statement as no clear benefit could be observed when adopting further substrate ablation strategy (ie, linear lesions and CFAE). 31 This apparent discrepancy could be explained by the recent experiences and the findings of the present study, as the abovementioned strategies may not be the correct target as they may not represent the adequate treatment in this subset of patients. 32, 33 Moreover, in the present study, the vast majority of regions exhibiting RRa were surrounded by fragmented activities, thus supporting the hypothesis that some fragmented electrograms might be expression of a passive activation instead of representing a critical target site. 20, 22, 23 The latter may explain why CFAE ablation has led to conflicting clinical outcomes as reported in the literature. 31, 33, 34 As occurred in this study, the novel integrated electrophysiological map may allow automated real-time characterization of multiple mechanisms during AF, by identifying regions exhibiting repetitive and regular activities, CV of consistent wave fronts, fragmentation, and electrically silent areas. These findings are relevant as they might characterize the respective contribution of different arrhythmogenic substrates within the pathological AF environment as it might lead to a better understanding of each patient-specific mechanism. However, why AF termination may not occur even with good long-term arrhythmia elimination and why complete drivers abolition may not result in acute AF termination in all the cases may warrant further investigation as it will certainly be matter of future research.
Limitations
This study is a single-center prospective randomized trial conducted in a relatively limited population; however, significant differences were demonstrated among the strategies. The strengths of the present study included an active control group (conventional mCPVA, rather than controls receiving previously ineffective drugs) and the extensive use of ICM (roughly 70%) in both groups. Arrhythmia recurrence rate and asymptomatic episodes might have been slightly underestimated by ECG Holter and patient-activated event ECG monitors.
In the present work, AF substrate map was performed using multiple sequential acquisitions at each location. Recent clinical studies have demonstrated that both panoramic 6, [8] [9] [10] and sequential mapping 7, 32, 33 techniques can be used to study AF activation patterns. Panoramic technique allows mapping the majority of chamber simultaneously, but with relatively lower resolution. Sequential mapping requires more mapping time, but it may promote better electrode-tissue contact and allows high-density mapping. The technique described in this study is based on the premise that the AF sources are spatially and temporally stable during the mapping time, as previously described. 9 For this reason, we think that sequential mapping can be reasonably considered a valid approach in the attempt to localize potential AF sources.
The software methodology used in this work filtered irregular electrograms from the repetitive and regular CL map. A potential limitation using this approach is the oversight of activations that are irregular, yet with repetitive temporal activations, that is, regions with intermittent suppression. Such regions were not considered in our present work and may certainly warrant further investigation. Moreover, in this study, a 5-to 10-s mapping time at each location was used. In our experience, this cutoff represented the best compromise to achieve significant electrophysiological information without significantly prolonging the total procedural time. It will be matter of future research to evaluate whether a longer mapping time (30-60 s) is necessary to better discriminate AF sources when using this novel technique.
Remapping after ablation was not regularly performed in all patients, preventing the possible identification of residual or de novo repetitive-regular sites. Furthermore, the interelectrode spacing of the mapping catheter had a 4 mm fixed distance that might underestimate the presence of faster drivers and smaller circuits. Considering also that the right atrium was not mapped, the presence of RRa in this chamber could have been missed, potentially limiting arrhythmia characterization and treatment outcome. However, this trial represents the pivotal experience using a novel mapping technique to prospectively identify and potentially eliminate LA AF sources, whereas right atrial mapping will be certainly matter of future research.
Conclusions
In this study, a novel integrated real-time 3D mapping technique, identifying regions exhibiting RRas, allows a patient-tailored ablation approach that provides an adjunctive benefit in terms of arrhythmia freedom at 1-year follow-up in the treatment of patients with PersAF when compared with conventional ablation approach. Future larger, randomized, multicenter studies with longer follow-up are necessary to assess the clinical role of this strategy.
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